Single dose palonosetron and dexamethasone in preventing nausea and vomiting induced by high emetogenic ABVD regimen in Hodgkin Lymphoma patients
Single dose palonosetron and dexamethasone in preventing nausea and vomiting induced by high emetogenic ABVD regimen in Hodgkin Lymphoma patients
复制标题
DOI：
10.1016/j.leukres.2011.06.025
复制
发表时间：
2012-02-01
影响因子：
2.7
通讯作者：
Bosi, Alberto
中科院分区：
文献类型：
--
作者：
Rigacci, Luigi;Landi, Carla;Bosi, Alberto
评价一种新的药物帕洛诺司琼在ABVD方案治疗霍奇金淋巴瘤患者中的疗效。在第一个ABVD周期的总阶段完全缓解是主要终点。次要终点为：急性期和总期无呕吐患者和抢救用药情况。2008年1月至2009年2月，共纳入36例患者。55.6%的患者达到了主要终点（CR 0-120 h）。总之，我们的研究表明，单剂量帕洛诺司琼加单剂量地塞米松对ABVD方案治疗的患者预防CINV有效。(C) 2011 Elsevier Ltd.版权所有。
To evaluate the efficacy of a new agent, palonosetron, in Hodgkin Lymphoma patients treated with ABVD regimen. Complete response during the overall phase of the first ABVD cycle, was the primary endpoint. Secondary end points were: emesis-free patients and use of rescue medication during the acute and overall phases. From January 2008 to February 2009 36 patients were enrolled. The primary endpoint (CR 0-120 h) was achieved by 55.6% patients. In conclusion our study demonstrated that a single dose of palonosetron plus a single dose of dexamethasone was effective in preventing CINV in patients treated with ABVD regimen. (C) 2011 Elsevier Ltd. All rights reserved.